• Like
  • Comment
  • Favorite

Bellway Ready for Recovery as Outlook Exceeds Results -- Market Talk

Dow Jones2024-10-15

0924 GMT - Although Bellway's results are in line with expectations its outlook for the year ahead exceeds them, RBC Capital Markets analyst Anthony Codling says in a note. The housebuilder is targeting delivery of at least 8,500 homes in FY 2025, compared with Visible Alpha consensus of 8,305 homes, and aims to retain a healthy forward order book for the year to support volume growth in FY 2026, he says. And it is ready to help the government's plan to deliver 1.5 million homes over the next five years and keen to grow its housebuilding business, Codling says. "Bellway believes it is well positioned to deliver strong multi-year growth against a backdrop of planning reform and improving housing market conditions," he says. Shares are up 7.6%, at 3,284 pence.(anthony.orunagoriainoff@dowjones.com)

 

(END) Dow Jones Newswires

October 15, 2024 05:26 ET (09:26 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

empty
No comments yet
errorbox banner

抱歉,当前请求异常(-1)

7x24

  • 20:42

    Medpace Holdings Inc - Amendment No. 7 Extends Revolving Credit Note to March 31, 2026 - SEC Filing

  • 20:42

    Medpace Holdings - Co Units Entered Amendment No. 7 to Loan Documents With PNC Bank - SEC Filing

  • 20:40

    Adverum Biotechnologies Inc - Company Expects to Report at Least One Material Weakness - SEC Filing

  • 20:40

    Adverum Biotechnologies Inc - Some Prior Financial Statements Should No Longer Be Relied Upon - SEC Filing

  • 20:39

    Repare Therapeutics: Lloyd M. Segal Resigned as President, CEO and Director

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email:uservice@ttm.financial